Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02010645 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02010645: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02010645 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02010645, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if eltrombopag given in combination with decitabine can help to control advanced MDS. The safety of this study drug combination will also be studied.
Interventions
- DRUG Decitabine
- DRUG Eltrombopag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-03 |
| Est. Completion | 2019-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02010645
The ClinicalTrials.gov registry entry for NCT02010645 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT02010645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02010645 about?
NCT02010645 is a clinical study titled "Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if eltrombopag given in combination with decitabine can help to control advanced MDS. The safety of this study drug combination will also be studied.
What is the current status of trial NCT02010645?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-03. Estimated completion is 2019-01-02.
What interventions are being tested in trial NCT02010645?
The interventions under investigation include: Decitabine (DRUG), Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT02010645?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.